AstraZeneca (LON:AZN) Given a £124 Price Target at Berenberg Bank

AstraZeneca (LON:AZNGet Rating) has been assigned a £124 ($151.13) target price by investment analysts at Berenberg Bank in a research report issued on Wednesday, Borsen Zeitung reports. Berenberg Bank’s target price indicates a potential upside of 15.41% from the stock’s current price.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group set a GBX 6,950 ($84.70) target price on AstraZeneca in a research note on Thursday, February 9th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, March 9th. UBS Group set a £119 ($145.03) target price on shares of AstraZeneca in a research report on Friday, March 10th. JPMorgan Chase & Co. set a £135 ($164.53) price target on shares of AstraZeneca in a report on Thursday, March 9th. Finally, Jefferies Financial Group set a £108 ($131.63) price objective on AstraZeneca in a report on Thursday, February 9th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of £118.85 ($144.85).

AstraZeneca Stock Up 0.5 %

Shares of LON AZN opened at £107.44 ($130.94) on Wednesday. AstraZeneca has a 12-month low of GBX 9,275 ($113.04) and a 12-month high of £128.28 ($156.35). The stock’s fifty day simple moving average is £111.13 and its two-hundred day simple moving average is £107.77. The stock has a market capitalization of £166.53 billion, a PE ratio of 6,139.43, a price-to-earnings-growth ratio of 1.31 and a beta of 0.17. The company has a current ratio of 0.86, a quick ratio of 0.59 and a debt-to-equity ratio of 84.02.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.